Definitive Healthcare (DH) Earnings Date & Reports

Key Takeaways

• Definitive Healthcare (DH) reported third-quarter 2026 revenue of $54.7 million, down about 9% from $60.0 million a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at $15.8 million, above the high end of the company's guidance range.
• Adjusted net income per diluted share was $0.06, topping management's $0.04–$0.05 outlook and the $0.04 consensus estimate.
• The GAAP net loss narrowed to roughly $5.4 million, a sharp improvement from the $17.8 million loss in the prior-year period.
• Operating cash flow and free cash flow softened year over year, reflecting continued pressure on the company's top line.
• For more context on this ticker's latest developments, explore the Major News, Today's Price Move, Price Targets, and Forecast pages.
• Looking for automated trade ideas? Explore Trending AI Robots to see how AI-driven strategies are approaching the market.

Earnings Context and Why It Matters

Definitive Healthcare is a provider of healthcare commercial intelligence, selling subscription-based data and analytics that help life sciences, provider, and diversified organizations understand the U.S. healthcare ecosystem. Its results are a useful signal for demand across healthcare software and data spending. The company has spent the past several quarters working through top-line contraction as customers trim budgets and shift toward shorter-duration contracts, even while management protects profitability through disciplined cost control. With revenue still declining in the high single digits, investors are watching closely to see whether improving retention and customer win-backs can translate into a return to growth, making each quarterly report a key checkpoint on the company's turnaround.

Reported Results

For the third quarter ended September 30, 2026, Definitive Healthcare posted total revenue of $54.7 million, a decline of roughly 9% from $60.0 million in the same period a year ago. The figure landed within the company's guidance range of $54.0–$55.0 million.

Profitability, however, came in ahead of expectations. Adjusted EBITDA was $15.8 million, equating to a 29% margin, above the guided range of $13.5–$14.5 million. Adjusted net income was $8.8 million, or $0.06 per diluted share, exceeding both the company's $0.04–$0.05 outlook and the $0.04 consensus estimate. Adjusted operating income was $12.8 million, down from $16.3 million a year earlier.

On a GAAP (Generally Accepted Accounting Principles) basis, the company's net loss narrowed to about $5.4 million, or $0.04 per share, from $17.8 million, or $0.14 per share, in the prior-year quarter. Adjusted gross margin was 81%, down modestly from 82% a year ago. Operating cash flow came in at $11.4 million, with unlevered free cash flow of $13.0 million, both lower than the comparable year-ago figures.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, helping reduce the time spent sifting through raw data. For investors tracking names like Definitive Healthcare, it offers a structured way to evaluate potential setups alongside other stocks in the healthcare technology space.

Market Reaction and Investor Sentiment

Sentiment heading into the report was cautious, reflecting a multi-quarter pattern of declining revenue offset by better-than-expected profitability. Definitive Healthcare's third-quarter results followed a familiar script: the top line continued to contract, but management once again outperformed on adjusted earnings and margin. The narrowing GAAP loss and above-guidance adjusted EBITDA are likely to be read positively, though persistent revenue declines and softer cash flow may temper enthusiasm. Investors will weigh the improved retention metrics and customer win-backs cited by management against the still-unresolved question of when organic growth will return, with the stock's reaction likely hinging on the company's updated fourth-quarter and full-year commentary.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should focus on whether Definitive Healthcare can stabilize its revenue base after several quarters of high-single-digit declines. Management has pointed to improving net dollar retention and customer win-backs as early signs of a turnaround, but converting those signals into sustained top-line growth remains the central challenge.

Margin management will stay in focus. The company has repeatedly raised its profitability guidance even as revenue softens, a trend worth monitoring to see whether cost discipline can continue offsetting lower sales without sacrificing investment in product and AI capabilities.

Key metrics to watch in the coming quarters include remaining performance obligations and deferred revenue, which provide visibility into future subscription activity, as well as any shifts in contract duration. Professional services demand, which has been a source of volatility, and the pace of recovery in the life sciences segment will also be important indicators. Guidance updates around full-year revenue and adjusted EBITDA will help clarify whether the company is on track for its return to growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations